Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and agree to sign a consent form
• People aged between 18 and 80 years old who are generally active and able to care for themselves (PS score 0–1)
• People who have been confirmed by tissue testing to have colorectal adenocarcinoma at a specific stage of disease, including some cases where cancer has spread to limited areas that surgeons assess as removable; the cancer must also have specific molecular features: a type called PMMR/MSS, a gene mutation called KRAS G12C, and no mutations in the NRAS or BRAF genes
• People with locally advanced colorectal cancer who have not previously received systemic (whole-body) treatment, or people with removable spread of cancer who have not previously received targeted therapy — though people who developed new spread after earlier adjuvant (preventive) chemotherapy may still be considered
• People whose blood test results meet minimum levels for red blood cells, white blood cells, and platelets (confirm with trial site for exact values)
• People whose liver and kidney function blood tests fall within acceptable ranges (confirm with trial site for exact values)
• People whose blood clotting and thyroid function tests fall within acceptable ranges (confirm with trial site for exact values)
• People whose heart pumping function, measured by an ultrasound of the heart, shows the heart pumping at least 50% of its capacity

Who may not be able to join:

• People whose cancer has a specific molecular feature called MSI-H or dMMR
• People whose cancer has spread to multiple areas in the body that cannot be surgically removed
• People who have had another cancer in the past 3 years (some exceptions may apply for certain early-stage or fully cured cancers such as cervical carcinoma in situ, certain skin cancers, or superficial bladder tumours — confirm with trial site)
• People who have had active inflammatory bowel disease in the 4 weeks before joining
• People with fluid build-up around the lungs, heart, or abdomen that cannot be controlled and requires repeated draining
• People who still have unresolved significant side effects from a previous cancer treatment (with some exceptions for hair loss or mild nerve-related side effects from a drug called oxaliplatin)
• People who have had a serious bleeding event, an unhealed wound, an active ulcer, or an unhealed fracture in the 4 weeks before the study starts
• People who have had a blood clot event in the past 6 months, such as a stroke, mini-stroke, deep vein clot, or a blood clot in the lungs
• People with a history of substance misuse involving mind-affecting drugs who are unable to stop
• People with serious uncontrolled health conditions, including: very high blood pressure that does not respond to treatment; significant heart disease including heart attack, irregular heart rhythm, or heart failure; serious active infection; liver cirrhosis or active hepatitis B or C (note: people with hepatitis B or C markers in their blood may still be considered if they are on continuous antiviral treatment — confirm with trial site); kidney failure requiring dialysis; HIV or other immune system conditions; organ transplant history; poorly controlled diabetes; significant protein in the urine; or a confirmed neurological or psychiatric condition requiring ongoing treatment, such as epilepsy or dementia
• People who have previously received targeted drug treatments, including KRAS G12C inhibitors or a drug called bevacizumab
• People who, in the opinion of the medical team running the trial, have other serious health concerns that could affect their safety or their ability to complete the study

Important: Always verify eligibility with the trial site directly before applying.